Post-marketing Surveillance of Spesolimab I.V. Infusion in improvement of Generalized Pustular Psoriasis (GPP) with acute symptoms in Japan (PMS for GPP with acute symptoms)

25/11/2022
16/11/2026
EU PAS number:
EUPAS49953
Study
Finalised
Documents
Study protocol
Initial protocol
English (1.48 MB - PDF) View document
Updated protocol
English (1.48 MB - PDF) View document
Study results
Study results
English (256.68 KB - PDF) View document
Study report
No information provided.
ENCePP Seal
No information provided.